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Abstract
Objective: To assess the coverage for cervical cancer screening as well as the use of cervical cytology, colposcopy and other
diagnostic and therapeutic interventions on the uterine cervix in Belgium, using individual health insurance data.
Methods: The Intermutualistic Agency compiled a database containing 14 million records from reimbursement claims for
Pap smears, colposcopies, cervical biopsies and surgery, performed between 2002 and 2006. Cervical cancer screening
coverage was defined as the proportion of women aged 25–64 that had a Pap smear within the last 3 years.
Results: Cervical cancer screening coverage was 61% at national level, for the target population of women between 25 and
64 years old, in the period 2004–2006. Differences between the 3 regions were small, but varied more substantially between
provinces. Coverage was 70% for 25–34 year old women, 67% for those aged 35–39 years, and decreased to 44% in the age
group of 60–64 years. The median screening interval was 13 months. The screening coverage varied substantially by social
category: 40% and 64%, in women categorised as beneficiary or not-beneficiary of increased reimbursement from social
insurance, respectively. In the 3-year period 2004–2006, 3.2 million screen tests were done in the target group consisting of
2.8 million women. However, only 1.7 million women got one or more smears and 1.1 million women had no smears,
corresponding to an average of 1.88 smears per woman in three years of time. Colposcopy was excessively used (number of
Pap smears over colposcopies = 3.2). The proportion of women with a history of conisation or hysterectomy, before the age
of 65, was 7% and 19%, respectively.
Conclusion: The screening coverage increased slightly from 59% in 2000 to 61% in 2006. The screening intensity remained
at a high level, and the number of cytological examinations was theoretically sufficient to cover more than the whole target
population.
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Introduction
For the year 2010, 593 new cases of cervical cancer (World-age
standardised rate (W-ASR) 7.5/100,000 women-years) were
reported by the Belgian Cancer Registry [www.kankerregister.
org/], and the most recent estimates for 2008 showed that
approximately 275 women (W-ASR 2.7/100,000 women-years)
died from the disease [1,2]. Age-period-cohort analyses revealed
an increased risk of cervical cancer for cohorts born after 1940,
that was counteracted partially by screening [3,4]. Through well-
organised cytological screening of high quality, the incidence of
cervical cancer can be reduced substantially [5–10]. In Belgium,
screening remained essentially opportunistic, which means that
Pap smears are taken at the spontaneous initiative of the woman,
her gynaecologist or her general practitioner [11,12]. Opportu-
nistic screening often results in a high level of overscreening and a
heterogeneous quality[13]. The Belgian cervical cancer screening
policy is adapted from European Guidelines and foresees one Pap
smear or liquid-based cytology sample every three years for
women of 25 to 64 years of age [14–16]. Nevertheless, the level of
adherence to this policy is rather poor, also in the Flemish
provinces where in the mid-1990s, a program was set up involving
invitation of women in the target age range 25-64 [11,12].
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Optimal attendance of the target population is one of the main
determinants of success of a screening program [17]. In the past, in
Belgium, this attendance could only be assessed by surveys [18,19].
Such surveys, involving collection of information directly from
women, are known to suffer from selection and reporting biases
that systematically result in overestimated coverage rates [20–22].
Recently, more reliable methods for estimating the population
coverage have become available through the compilation of health
insurance data by the Intermutualistic Agency (IMA). In a
previous report, IMA data were used to assess the cytological
screening coverage, as well as the consumption of medical acts
related to collection and interpretation of Pap smears, and follow-
up or treatment of women with cervical lesions, comprising the
period 1996-2000. The current study completes the 1996-2000
report [12], allowing assessment of the cervical cancer screening
activity in Belgium for more than a decade.
Methods
Health insurance in Belgium is mandatory, covering the whole
Belgian population, and is mediated by "sickness funds" that
arrange reimbursements and keep track of all reimbursed medical
acts [12]. Upon request of the Scientific Institute of Public Health
(Brussels, Belgium), a data file containing more than 14 million
individual patient reimbursement records was compiled by the
Intermutualistic Agency (IMA). This data file contained all
medical acts related to cervical screening and diagnostic or
therapeutic interventions on the uterine cervix (Pap smear
collection and interpretation, colposcopies, cervical biopsies and
their interpretation, surgery on the cervix) performed on women
resident in Belgium, between 2002 and 2006. The database
incorporates medical acts performed in all types of services (private
physicians, group practices, private and public outpatient clinics
and hospitals), but does not contain diagnostic or clinical
information.
A numerical individual ID code, age, date of the act, residence
of the woman, and type of the medical act was provided in the
data set. The ID code was a unique number, allowing tracing
multiple consecutive Pap smears and other acts for the same
woman. For the respect of privacy, data details were truncated to
reduce the risk of obtaining cells of cross tables with small counts
(,5). Age was converted into the respective five-year age group at
the exception of the group 0–14 and the 75+ age group, which
were each grouped into one category. The calendar date of the act
was restricted to the year of the act at the exception of the
collection of cervical cell specimen, where also the month was
available. The residence was restricted to the province. Contrary
to the previous analysis of the period 1996–2000, the social status
was provided, whereas the geographical detail of district was
restricted to province. Social status was categorised as following:
beneficiary of increased reimbursement (BIR), normal status,
unknown or censored status. Increased reimbursement is foreseen
for vulnerable social categories such as orphans, widows, aged or
retired people, and individuals being unemployed for long delays,
with a handicap and low income.
Screening in Belgium
Cervical cancer screening during the study period was cytology-
based [11,12]. In spite of clinical guidelines proposing one Pap
smear every three years for women aged 25–64 years, no
restriction was imposed regarding reimbursement. Invitations
were sent to women of the target population in last halve of the
1990s in all five provinces of Flanders (Northern Belgium), but this
was continued during the study period in only two of them
(Antwerp and Flemish-Brabant).
Colposcopy was recommended in case of a first observation of
high-grade squamous intraepithelial lesion (HSIL), atypical
glandular cells (AGC) or HPV-positive ASC-US, or after a second
observation of atypical squamous cell of undermined significance
(ASC-US) or low-grade squamous intraepithelial lesions (LSIL)
[23,24]. The prevalence of these lesions, estimated from a
comprehensive provincial cervical cytology registry was: 0.4%
for HSIL, 1.1% for LSIL, 2.2% for ASCUS and 0.1% for atypical
glandular cells [25]. Professional guidelines were in place
regarding diagnostic and therapeutic work-up [26].
Statistical analyses
Data were aggregated by age groups and geographical levels
and combined with the respective mid-period female population
size, obtained from the Directorate General Statistics and
Economic Information (DGSEI, formerly known as the National
Institute of Statistics, Brussels, Belgium) to compute proportions or
incidence rates. The following geographical levels were distin-
guished: the whole country, the three regions (Flemish Region,
Capital Region of Brussels, and the Walloon Region) and the
eleven provinces.
Cervical cancer screening coverage was defined as the
proportion of the target population (women of 25–64 years) that
had a cervical cytology examination within the last 3 years.
Overuse (or excess use) was defined as the proportion of cervical
cytology specimen taken in the target group that did not
contribute to the coverage (number of smears taken in 3-years
time/number of women screened in that period – 1)*100.
For the computation of the cumulative incidence of conisation
or hysterectomy until a given age k, the following formula was
applied:
Cumulative incidence~ 1{P
k
k~1
(1{ eai :DT )
where P stands for cumulative product, ai for age-specific
incidence, and DT for the amplitude of the age categories [27].
Results
Screening coverage
The 3-year cervical cancer screening coverage in the target
population (25-64y), assessed over the period 2004-06, was 61%.
Similar to the preceding analysis (1996–2000), the range of
variation in screening coverage at the level of the Regions was
small: 60% in the Flemish Region, 62% in the Brussels-Capital
Region and 63% in the Walloon Region. The variation in
coverage, measured as an absolute difference in proportions, over
the period 2002–2006, was very limited (+0.5% for the whole
country), with a small increase in the Flemish (+0.8%) and
Walloon Region (+0.5%) and a decrease in the Brussels-Capital
Region (–0.4%) (Table 1). Differences at provincial level were
more substantial, with a screening coverage, observed in 2006,
ranging from 51% (Luxembourg) to 70% (Walloon-Brabant).
Overall, the screening coverage increased with 2.2% compared
to 2000. This increase was more pronounced in the Brussels-
Capital Region (+4.3%) and between 2 and 3% for the other two
regions. In most provinces, the screening coverage increased
(between 0.9% and 4.3%), at the exception of 2 provinces where a
small decrease was noted (Limburg (–0.2%) and Luxemburg (–
0.3%)).
Cervical Screening and Related Interventions (Belgium)
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Age groups
At the national level, the youngest age groups (women of 25–34
years old), were the best screened with a coverage of 70%. From
the age of 35 to 49, the coverage decreased gradually from 67% to
62%. From the age of 50, the coverage dropped more steeply to
reach 44% in the age group 60–64 (Figure 1). The age profile was
similar in the three regions. However, in the Brussels-Capital
Region and Walloon Region the decline in the age group 50–64
was less pronounced than in the Flemish Region.
Screening interval and screening beyond the target age
range
The median screening interval was 13 months (inter-quartile
range: 11–22 months). A time span of 36 months or more was
observed in only 3% of women with 2 or more smears in the
studied time period, whereas in 30% it was less than 12 months.
Screening beyond the target age range contributed 18% of all
smears: 10% from women younger than 25 years and 8% from
women aged 65 or older. In the age groups 15–19 and 20–25, the
screening coverage was 17% and 52%, respectively. A coverage of
31% and 21% was noted in the older age groups 65–69 and 70–
74, respectively (see Figure 2).
Social status
In the whole Belgian target population, the screening coverage
was respectively 40% in women who benefited from increased
reimbursement for health care (BIR) compared to 64% for women
who did not benefit from increased reimbursement (non-BIR).
The differences between the two social categories (non-BIR - BIR)
were consistent over all geographical areas and all groups, but
varied in magnitude. At regional level, the difference varied
between 21% (Brussels-Capital Region) and 27% (Flemish
Region). At provincial level, the difference ranged between 21%
(Brussels) and 33% (Walloon-Brabant). The contrast changed also
by age group: in the range 22–25% for women aged 25–44 years
and less for younger and older women (Figure 3).
Consumption of Pap smears
For the period 2004–2006, the ratio of the number of Pap
smears over the size of the target population was 1.15. In absolute
figures: 3.2 million Pap smears were interpreted in the period
2004–2006 which were taken from only 1.7 million women. One
million and seventy nine thousand women, accounting for 39% of
the target group, did not get a Pap smear in this three-year period.
The excess use of cervical cytological examinations was 88%,
which means that each screened women received on average 1.88
smears over a time span of three years. The excess smear use was
high in all parts of Belgium. However, it was less high in the
Flemish Region (84%), highest in the Capital Region (95%), and
intermediate in the Walloon Region (92%) (Table 1).
Profession of smear takers
Eighty nine percent of cervical cell specimens were collected by
gynaecologists. The proportion of Pap smears prepared by general
practitioners (GPs) was low and varied substantially by Region. In
a decade (1996–2006), the contribution of GPs decreased
continuously: from 26% to 14% in the Flemish Region, from
10% to 7% in Brussels and from 5% to 2% in the Walloon Region.
Colposcopy use
One colposcopic examination was charged for every 3.2 Pap
smears, at the national level. This ratio varied regionally between
7.8 (Flemish Region) and 1.6 (Walloon Region) (Table 2). At
provincial level, the lowest Pap smear/colposcopy ratio was
observed in Hainaut and Lie`ge (1.6) and the highest in Antwerp
(11.4).
The biopsy/colposcopy ratio was low (on average 5%), due to
the very high frequency of not-clinically indicated colposcopies
(Table 2).
Conisations
The age-specific incidence of excisional treatment for cervical
precancer (by conisation or large loop excision of the transforma-
tion zone) and the cumulative incidence of treatment up to a given
Figure 1. Variation of the screening coverage and the # smears/ # women ratio considered over a 3-year interval, by 5-year age
group (Belgium, 2004-06).
doi:10.1371/journal.pone.0092615.g001
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age is shown in Figure 4. Only the first conisations were taken into
account. The incidence of conisation peaks in the age group 30–34
years (3.0/1000 women-years). Up to the age of 34 years, 3.7% of
women have had a history of conisation. Up to the age of 65, this
proportion was 7.3%.
Hysterectomies
The incidence of hysterectomy was highest in the age range 40–
54 years: 7.3, 9.2, and 6.3 per 1000 women-years in age groups
40–44, 45–49, and 50–54 years, respectively (Figure 5-left). Up to
the age of 49 years, 14.8% of women have their uterus, including
their cervix, removed (Figure 5-right). Up to the age of 64, this
proportion was 18.7%.
Figure 2. Distribution of the time interval between successive collections of cervical cytology specimen.
doi:10.1371/journal.pone.0092615.g002
Figure 3. Three-year screening coverage by age and by socio-economic status, defined as beneficiary or not beneficiary of
increased reimbursement (BIR), Belgium, 2004–2006.
doi:10.1371/journal.pone.0092615.g003
Cervical Screening and Related Interventions (Belgium)
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The shape of the curves was similar for the three regions.
However, the age-specific incidences were substantially higher in
the Flemish and Walloon Regions, compared to the Brussels-
Capital Region. Peak incidences, in the 45–49 year age group
were 9.4, 9.0, and 7.4 per 1000 women-years in the Flemish,
Walloon and Brussels-Capital Region, respectively.
Nineteen percent of women of 20 years or older, hysterecto-
mised in 2002, had at least one Pap smear taken in the subsequent
three years.
Discussion
Screening coverage, intensity of screening
This report (2002–2006) shows results similar to those of the
previous analysis (1996–2000) [12]. In 2006, at the national level,
61% of women 25–64 years old had received a Pap smear in the
last 3 years, what is only 2% higher compared to 2000. The
screening coverage was substantially lower among socially
vulnerable groups: 40% among women with BIR, whereas 64%
among women without BIR.
The slightly higher coverage in the Walloon Region compared
to the Flemish Region observed in 1996–2000 was maintained,
which is remarkable, given the fact that in the latter region a
screening campaign was organised since the mid-1990s. The
intensity of the invitations was relaxed in the Flemish provinces
after 2000: it was maintained in Antwerp and Flemish-Brabant,
and completely interrupted in East-Flanders. No obvious impact of
sending invitations to women was seen. For, instance: the increase
in screening coverage observed between 2000 and 2006 was
+2.6% in East-Flanders and only +1.8% in Flemish-Brabant.
Also the excess use of Pap tests hardly changed over time. This
overuse has a substantial impact on the public health budget
without clear benefit in terms of incidence or mortality reduction
compared to a more conservative screening as recommend in
European guidelines [28–30].
Colposcopies
An impressive amount of colposcopies are performed in
Belgium. Although the main purpose of colposcopy is to assist in
the diagnosis of precancer in women with a previous cytological
abnormality, it is often performed at the same time of the
collection of a screening Pap smear. Colposcopy was obviously not
used according to accepted guidelines [23,24] However, a small
relative decrease was observed over time in the use of colposcopy.
One colposcopy was performed per 2.9 Pap smears, in 2000,
versus 3.2 Pap smears/colposcopy, in 2006.
Conisations
Over-consumption of screen tests, inevitably generates unnec-
essary follow-up examinations (repeat Pap smears, colposcopies,
biopsies) and treatment of lesions. Excisional treatment of cervical
intraepithelial neoplasia (CIN), in particular deep excisions beyond
10 mm of depth, may be associated with an increased risk of
preterm delivery [31–34,34]. Under the assumption that pregnant
Table 2. Number of colposcopies, cervical biopsies, and Pap smears; ratio of the number of biopsies over the number of
colposcopies, ratio of the number of Pap smears over the number of colposcopies, and ratio of the number of biopsies over the
number of Pap smears, Belgium, 2002–2006.
Biopsy/ Pap/ Biopsy/
Pap colposcopy colposcopy Pap
Region Colposcopies Biopsies smears ratio ratio ratio
Flemish Region 441,027 48,559 3,456,854 0.110 7.8 0.014
Brussels-Capital Region 229,164 12,460 677,749 0.054 3.0 0.018
Walloon Region 1,292,537 30,654 2,230,035 0.024 1.7 0.014
Whole of Belgium 1,980,927 93,773 6,417,936 0.047 3.2 0.015
doi:10.1371/journal.pone.0092615.t002
Figure 4. Incidence of conisation by age (left); cumulative incidence of conisation up to a given age (right) in Belgium, 2002–2006.
doi:10.1371/journal.pone.0092615.g004
Cervical Screening and Related Interventions (Belgium)
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women previously treated with LLETZ exceeding 10 mm have a
risk of preterm delivery (PD) that is at least 1.5 times higher than
for non-treated pregnant women [31,33]. Taking into account the
maternal age distribution at delivery [35], and the cumulative
incidence of conisation over age (figure 4-right), we can estimate
that 1.5% of all PDs in Belgium are attributable to prior LLETZ.
However, among treated women, the risk of PD attributable to
deep LLETZ excisions may be about 33%.
The incidence of conisations increased in Belgium from 1.3/
1000 women years in 2000 to 1.7/1000 in 2006.
Hysterectomies
No further screening is required for women who have
undergone a total hysterectomy for a non-oncological indication.
However, 26% of women aged 25–64 years, hysterectomised in
2002, had at least one Pap smear taken in the next three years.
From other sources, it was estimated that 13% of total
hysterectomies in Belgium are performed for a malignant
indication, so these women can be considered as still requiring
cytological testing. Unfortunately, the data provided by IMA do
not provide the indication of the hysterectomy. In a survey in the
United States, it was noted that 64% of hysterectomised women
were still cytologically screened [36]. In Belgium, over-screening in
women without cervix is substantially lower.
The incidence of hysterectomy decreased slightly over time (5.0
and 4.8 per 1000 women-years aged 25–64 years, in 2000 and
2006, respectively).
Strengths and limitations of the study
Data details were truncated to reduce the risk of identifiability.
This truncation impeded computation of indicators at district or
municipality level.
No data were obtained for 2001 and the ID coding was different
between the two study periods (1996–2000 and 2002–2006),
impeding computation over more than five years.
The received IMA data contained only administrative content
and were not linkable with medical registries. It must be remarked
that organised population-based screening, includes by definition
registration of individual data with the possibility of linkage
between population-, screening-, cancer- and mortality-registers.
The Belgian privacy protection law in principle does not allow
registration of personal medical data but includes derogations
specifically for population screening [37]. Moreover, since 2010,
all cytopathology laboratories in Belgium are mandated, by law, to
communicate all cyto-pathology results related to cancer screening
to the National Cancer Registry [38]. So in the future, more in-
depth evaluation of screening indicators will be possible, as
recommended in European guidelines [16].
A major strength of the study comes from the exhaustivity of the
IMA database allowing more reliable evaluation of the screening
coverage than surveys. The national health interview surveys,
conducted in 2004, reported a coverage of 72%, which was 12%
higher than the estimate derived from the IMA database for that
year [19,28]. This discrepancy is probably due to reporting biases,
which are inherent to interview surveys resulting in inflated
coverage estimates [39–41].
Structural propositions for the future
Measures foreseen in the European Council Recommendation
on Cancer screening should be binding and applied in all the
Belgian regions. The fact that hardly any evolution in screening
indicators was observed over the last ten years, demonstrates the
necessity of a well-organised cervical cancer screening programme
and clear information for the physicians and women. Health
authorities of the Federal and Community Governments and
representatives of the scientific societies should define as soon as
possible a rational, evidence-based and cost-effective cervical
cancer screening policy for Belgium. In the context of the actual
opportunistic screening, an organised cervical cancer screening
programme should deal with the questions linked with the two
major problems identified in the current study: (1) How can the
excess consumption of Pap smears among currently screened
women be reduced? (2) How can the 39% of the target population
that is currently not covered be reached and convinced to
participate regularly at recommended intervals.
How to decrease over-screening?
In the meanwhile, reimbursement conditions in Belgium have
changed. Previously, Pap smears were reimbursed without any
interval restrictions, but since May 2009, two different types of
cervix cytology examinations were distinguished: a) screening
(minimum interval of 2 years) and b) follow-up (maximum 2 per
year) [42]. A small financial contribution was paid by the
individual concerned. The implementation of this regulation has
reduced dramatically the total volume of cervical cytology
examinations performed: from 1.37 million in 2008 to 0.81
million in 2010, or a reduction of 41%. In March 2013, a new
Royal Decree was published that restricted reimbursement of
screening cytology to once every three years. This three-yearly Pap
smear is now completely free of charge [43]. Matching
reimbursement regulations to recommended screening intervals
appears to have had a tremendous effect. How these new
Figure 5. Incidence of total hysterectomy by age (left); cumulative incidence of total hysterectomy up to a given age (right) in
Belgium, 2002–2006.
doi:10.1371/journal.pone.0092615.g005
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regulations influenced the screening coverage and the average Pap
smears/screened woman ratio has to be assessed in the third IMA
report on cervical cancer screening. It should be noted, however,
that some amount of over-screening, not reimbursed but paid by
the woman herself, may occur.
How to increase screening coverage?
As mentioned above, the impact of sending invitation letters
with a recommendation to have a Pap smear taken, probably has
had only minor effects on screening coverage. A working
hypothesis is that GPs can play a role in reaching women who
do not attend at screening. In a telephone survey, conducted in the
Flemish Region, screened women indicated their gynaecologist as
preferred smear taker, whereas non-screened women would accept
the proposal of a GP to have a Pap smear taken [18]. These data
provide substance for the working hypothesis. However, structural
measures must be taken to create conditions promoting proactive
preventive care, including secondary prevention of cervical cancer,
to be offered systematically by the GP to his/her patients. The
limited proportion of Pap smear taken by GPs, in particular in the
Walloon Region, indicate that mobilizing GPs in efforts to increase
screening coverage is not an easy issue.
Offering self-sampling kits for HPV testing to non-screened
women is another strategy, which can induce coverage increase
[44]. However, this should be carefully tested in pilot projects
before considering general introduction. Moreover, a strategy
requires a well-organised environment to be successful.
Conclusions
Individual health insurance data makes up an enormous
resource for epidemiological research and program evaluation in
general and, in particular allows a precise estimate of the
population coverage and the consumption of related medical acts.
This second IMA report reveals substantial overconsumption of
resources with limited health benefits. The national cervical cancer
screening coverage just reached 61%, but the number of smears
was sufficient to cover more than the whole target population. The
coverage varied slightly between regions but more substantially
between provinces. However, no obvious evidence of an impact of
the invitational programs set up by Flemish provinces could be
discerned. The excessive use of low-cost colposcopy is striking..
Pre´cis
The amount of Pap smears examined is sufficient to cover the
whole target population, however 39% is not covered. Substantial
overconsumption of colopscopies is noted.
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